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Abstract
Objective
To determine the disease relevance of a novel de novo dominant variant in the SLC25A4 gene,
encoding the muscle mitochondrial adenosine diphosphate (ADP)/adenosine triphosphate
(ATP) carrier, identified in a child presenting with a previously unreported phenotype of mild
childhood-onset myopathy.
Methods
Immunohistochemical and western blot analysis of the patient’s muscle tissue were used to
assay for the evidence of mitochondrial myopathy and for complex I–V protein levels. To
determine the effect of a putative pathogenic p.Lys33Gln variant on ADP/ATP transport, the
mutant protein was expressed in Lactococcus lactis and its transport activity was assessed with
fused membrane vesicles.
Results
Our data demonstrate that the heterozygous c.97A>T (p.Lys33Gln) SLC25A4 variant is
associated with classic muscle biopsy findings of mitochondrial myopathy (cytochrome c
oxidase [COX]-deficient and ragged blue fibers), significantly impaired ADP/ATP transport in
Lactococcus lactis and decreased complex I, III, and IV protein levels in patient’s skeletal muscle.
Nonetheless, the expression levels of the total ADP/ATP carrier (AAC) content in the muscle
biopsy was largely unaffected.
Conclusions
This report further expands the clinical phenotype of de novo dominant SLC25A4mutations to
a childhood-onset, mild skeletal myopathy, without evidence of previously reported clinical
features associated with SLC25A4-associated disease, such as cardiomyopathy, encephalopathy
or ophthalmoplegia. The most likely reason for the milder disease phenotype is that the overall
AAC expression levels were not affected, meaning that expression of the wild-type allele and
other isoforms may in part have compensated for the impaired mutant variant.
*These authors contributed equally to the manuscript.
From the Medical Research Council Mitochondrial Biology Unit (M.S.K., E.R.S.K.), University of Cambridge, Wellcome Trust/MRC Building, Cambridge Biomedical Campus, UK;
Wellcome Centre for Mitochondrial Research (K.T., S.H., L.H., R.W.D.), Institute of Neuroscience, Newcastle University, UK; and Department of Neurology (X.R.O.), Perelman School of
Medicine, Division of Neurology and Center for Mitochondrial and Epigenomic Medicine, The Children’s Hospital of Philadelphia, University of Pennsylvania.
Funding information and disclosures are provided at the end of the article. Full disclosure form information provided by the authors is available with the full text of this article at
Neurology.org/NG.
The Article Processing Charge was funded by the Wellcome Centre for Mitochondrial Research.
This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. 1
SLC25A4 (ANT1 and AAC1) gene mutations cause an in-
triguing spectrum of human disease, with dominant mutations
first reported in adults with progressive external oph-
thalmoplegia (PEO),1 whereas recessive loss-of-function
mutations cause cardiomyopathy and skeletal myopathy.2,3
Furthermore, SLC25A4 de novo dominant mutations can
present in neonates with lactic acidosis, severe hypotonia, and
respiratory failure.4 Here, we report a patient who presented
at age 2 years with mild weakness and hypotonia and was
found to have a novel de novo heterozygous SLC25A4 variant
(c.97A>T;p.Lys33Gln).
The SLC25A4 gene encodes the mitochondrial AAC1, which
imports ADP into the mitochondrion and exports ATP.5
Humans have 4 AAC isoforms, with AAC1 being specific to
the heart, skeletal muscle, and brain.6 Previous functional
studies correlating the rate of ADP/ATP exchange with
phenotype severity have only partially solved the puzzle. In
dominant-acting mutations, the rate of transport does seem to
correlate with clinical severity, with mutations associated with
PEO having higher residual ADP/ATP transport rates com-
pared with de novo mutations associated with severe neonatal
disease.4 However, loss-of-function recessive mutations
present later than de novo cases with a predominant cardiac
phenotype, despite in vitro functional studies showing es-
sentially no measurable ADP/ATP exchange4
Here, we report that the de novo dominant variant
p.Lys33Gln in SLC25A4 is clinically associated with mild
myopathy despite significant mitochondrial pathology in
muscle biopsy and functional data showing abolished ADP/
ATP exchange in vitro. This case expands the known phe-
notype of SLC25A4 disease to include childhood-onset mild
skeletal myopathy without evidence of cardiac, brain, or
extraocular muscle involvement.
Methods
Case presentation
A 2-year old girl presented to the neurology clinic at the
Children’s Hospital of Philadelphia (CHOP) for hypotonia
and mild gross motor delays. Neurologic examination at
presentation was only remarkable for hypotonia and a 1-
handed Gower maneuver, suggestive of mild weakness.
Family history was unremarkable. Laboratory workup found
elevated creatine kinase (CK) (616 U/L, normal 60–305) and
lactic acidosis (3.76 mM, normal 0.8–2.0) levels; therefore,
muscle biopsy and subsequent genetic testing were pursued.
Clinical testing for nuclear mitochondrial disease genes and
full mitochondrial DNA (mtDNA) sequencing (in blood and
muscle) were obtained via the next-generation sequencing
panel.
Standard protocol approvals, registrations,
and patient consents
Informed consent was obtained from the child’s parents to
enroll in a human subject’s research protocol approved by the
Institutional Review Board at CHOP.
Human muscle immunohistochemistry
and analysis
Standard histologic and histochemical analyses were per-
formed on 10-μm transversely oriented muscle cryosections.
Quadruple immunofluorescence analysis of NDUFB8
(complex I) and COXI (complex IV)7 and western blot
analysis3 were performed as previously reported. mtDNA
copy number assessment in muscle was undertaken as
described.8
Functional studies of p.Lys33Gln variant in
Lactococcus lactis
The SLC25A4 gene was cloned into the L. lactis expression
vector pNZ8048 by established procedures,9 and the
p.Lys33Gln variant was introduced and confirmed by se-
quencing. Growth of L. lactis, membrane isolation, vesicle
preparation, transport assays, and western blot analysis were
performed as reported.4,9
Results
Patient results
Histopathologic assessment of skeletal muscle from the pa-
tient demonstrated a mosaic pattern of cytochrome c oxidase
(COX) deficiency (figure 1A). Quadruple immunofluores-
cence analysis confirmed a mitochondrial defect involving
both complexes I and IV with some fibers exhibiting normal
protein expression (figure 1B). MtDNA copy number was
decreased to approximately 40% in patient muscle compared
with age-matched controls. Western blot analysis showed
a slight decrease in AAC protein levels, associated with more
markedly decreased steady-state protein levels of components
of respiratory complexes (CI, CIII, and CIV) in patient
skeletal muscle (figure 1C).
Genetic testing revealed a heterozygous SLC25A4 variant
(c.97A>C, p.Lys33Gln) that was confirmed to have arisen de
novo following parental testing. Serial cardiac evaluations
including ECG, echocardiogram, and Holter monitoring were
unremarkable from diagnosis at age 2 years to current age of 8
Glossary:
AAC = ADP/ATP carrier; ADP = adenosine diphosphate; ATP = adenosine triphosphate; COX = cytochrome c oxidase;
CHOP = Children’s Hospital of Philadelphia; CK = creatine kinase; mtDNA = mitochondrial DNA; OXPHOS = oxidative
phosphorylation; PEO = progressive external ophthalmoplegia.
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years. Neurologic evaluations remain stable, only remarkable
for mild proximal weakness, hyperCKemia, and lactic acidosis,
with normal extraocular movements and no cognitive
abnormalities.
Assessment of SLC25A4 p.Lys33Gln
variant function
The transport mechanism of SLC25A4 involves the disrup-
tion and formation of the matrix and cytoplasmic salt bridge
network in an alternative way (figure 2A).5 Residue Lys33 in
SLC25A4, which is conserved among AAC from fungi, plants,
and metazoans (figure 2B), forms a salt bridge with the
conserved Asp232 in the matrix network (figure 2, C and D).
The p.Lys33Gln mutation would eliminate this interaction, as
glutamine is a neutral amino acid residue and too short to
form a hydrogen bond (figure 2E). Below the salt bridge is
Gln37 that forms a highly conserved glutamine brace10 (figure
2, B–D), which would also be disrupted by the mutation
(figure 2E).
We introduced the p.Lys33Gln mutation into the human
SLC25A4 sequence and expressed it L. lactis membranes. The
uptake of radio-labeled ADP in exchange for loaded ADP was
measured for an empty vector control (figure 3A), wild-type
SLC25A4 (figure 3B), and p.Lys33Gln, using the specific in-
hibitor carboxyatractyloside as control (figure 3C). Themutant
protein is expressed to approximately the same levels as wild-
type in lactococcal membranes, suggesting that the mutation
does not affect biogenesis, protein folding, or targeting to
the membrane in this expression system (figure 3D). The
p.Lys33Glnmutant was not able to transport ADP (figure 3E).
Discussion
Previously, we have functionally characterized the effect of 9
pathogenic variants in human SLC25A4 using L. lactis, de-
termining residual transport activity compared with wild-type
protein.4 Broadly speaking, residual transport activities of the
mutants segregate with the associated clinical phenotype;
mutations associated with adult-onset dominant PEO display
higher residual transport activities (24%–56%) than muta-
tions associated with recessive disease, which were effectively
nonfunctional.4 There was also a correlation between the
severity of the clinical phenotype and residual transport ac-
tivity of previously documented dominant mutations, with
Figure 1 The de novo p.Lys33Gln mutation leads to OXPHOS defect in muscle
(A) Histopathologic analysis of patient skeletal muscle sections showing hematoxylin and eosin (H&E) staining (far left), COX histochemistry (middle left), SDH
histochemistry (middle right), and sequential COX-SDH histochemistry (far right). Scale bar = 100 μm. (B) Respiratory chain profile following quadruple oxidative
phosphorylation immunofluorescence analysis of cryosectionedmuscle from the index case, confirming the presence of fibers lacking complex I (NDUFB8) and
complex IV (COXI) protein. Each dot represents the measurement from an individual muscle fiber, color coded according to its mitochondrial mass (blue-low,
normal-beige, high-orange, and very high–red). Gray dashed lines indicate SD limits for the classification of fibers. Lines next to x- and y-axes represent the levels
(SDs from the average of control fibers after normalization to porin/VDAC1 levels; _z= Z-score, see Methods section of Rocha et al. 2015 for full description of
statistics7) ofNDUFB8andCOX1, respectively (beige=normal [>−3], light beige= intermediatepositive [−3 to−4.5], light purple = intermediate negative [−4.5 to−6],
and purple = deficient [<−6]). Bold dotted lines indicate the mean expression level observed in respiratory normal fibers. (C) Western blot analysis of AAC and
OXPHOS complex subunits on control andpatient skeletalmuscle samples. AAC= ADP/ATPcarrier; ADP= adenosinediphosphate; ATP = adenosine triphosphate;
COX = cytochrome c oxidase; GADPH = Glyceraldehyde 3-phosphate dehydrogenase; OXPHOS = oxidative phosphorylation; SDH = succinate dehydrogenase.
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Figure 2 The p.Lys33Gln mutation eliminates a conserved salt bridge interaction of the matrix network
(A)Transport cycleof themitochondrialAACSLC25A4.Thedisruptionandformationof salt bridgesbetweenpositively (blue)andnegatively (red) chargedresiduesof the
cytoplasmic andmatrix networks, top and bottom respectively, change the access of the substrates to the central substrate binding site, indicated by a hexagon, from
the intermembranespace (i) andmatrix (m) sideof themembrane. The importedADP is shown ingreensphere representationand theexportedATP incyan. (B)Amino
acid sequence alignment of AAC1 sequences of fungi, plants, and metazoan, showing that Lys33, Gln37, and Asp232 are highly conserved amino acid residues. (C)
Lateral view of the human ADP/ATP carrier from the membrane, showing the residues of the matrix and cytoplasmic networks (blue and red sticks) and substrate
binding site (green sticks, hexagon). ADP (light blue ball and stick) and the glutamine brace (light green stick) are also shown. Residue Lys33 that ismutated is shown in
yellow. (D) Cytoplasmic view of the carrier showing only the residues of the matrix salt bridge network of SLC25A4 (blue and red sticks). (E) As (D), except for the
p.Lys33Glnmutation, which is shown inmagenta. The ionic interactions (black dash lines) are indicated with plus andminus signs. Themodel of human SLC25A4was
generated in SwissModel, using the structure of the closely related bovinemitochondrial AAC as template (PDB file: 1OKC). Adapted fromFigure 3 in reference 4. AAC =
ADP/ATP carrier; ADP = adenosine diphosphate; ATP = adenosine triphosphate.
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mutations associated with inherited PEO showing higher
activity than mutations associated with de novo severe neo-
natal presentation.3
It remains unclear exactly why the presently documented case
with the de novo dominant c.97A>T(p.Lys33Gln) SLC25A4
variant presents with a much milder clinical phenotype than
the other de novo cases3 despite the p.Lys33Gln mutant
protein revealing essentially null ADP/ATP transport activity
(figure 3E). This case further supports that residual ADP/
ATP transport activity of mutant AAC1 is only part of the
puzzle. In vivo, there are 3 other AAC isoforms with varying
expression levels in different tissues. Also, since the de novo
variants are heterozygous, the relative expression ratios of
wild-type vs mutant AAC1, as well as other isoforms, will have
an effect on the overall transport capacity. Their relative ex-
pression levels of carriers cannot be assessed from messenger
RNA levels, as there are many poorly characterized steps in-
volved in their biogenesis and turnover, and the available anti-
bodies are unable to distinguish between the various isoforms.
Despite these issues, there is a clear correlation between the
severity of OXPHOS dysfunction in skeletal muscle and the
clinical phenotype between the current and previously
reported de novo mutations. Patients with p.Arg80His or
p.Arg235Gly mutations, showing severe neonatal pre-
sentations, had markedly decreased levels of total AAC
(<30%),3 whereas there is only a slight decrease in the current
patient (figure 1C). Similarly, the mosaic pattern of OXPHOS
deficiency (figure 1, A and B) is not seen in previously
documented de novo cases, where steady state protein levels
of various OXPHOS components were completely
undetectable.3 These data suggest that the clinical severity of
de novo dominant mutations in SLC25A4 could be explained
by the relative expression of wild-type and mutant alleles and
the expression of other AAC isoforms, rather than the
transport activity of the mutant variant alone.
This report expands the clinical phenotype for SLC25A4-
associated mitochondrial disease, with the mildest childhood-
onset presentation to date.
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